Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Stock Screener   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in
Register now or login to post to this thread.

SkyePharma to report maiden profit in April ? (SKP)     

Slacker - 18 Feb 2003 09:52

Anybody else out there interested in these?

2002 Results are due in April, and they are expected to show a maiden profit.
Last week I opened a small speculative long (spreadbet), but I am looking to add to this position a lot more if we get any sort of resolution over Iraq crisis before the results which should spark a broad market rally from which SKP could really benefit and have a strong run-up.

DYOR etc.

Here is a recent research note from Merrill Lynch (they estimate 0.25p EPS for 2002):

Merrill Lynch FlashNote

7 February 2003


Newsflow Set To Continue BUY

Reason for Report: Company Update

EPS (Dec): 2001A -1.19p; 2002E 0.25p; 2003E 2.13p
P/E (Dec): 2001A NM; 2002E 180.0x; 2003E 21.1x

Michael Ashton, CEO SkyePharma, gave an upbeat and informative presentation today.

Depomorphine appears on track for US submission in June 03. The two pivotal trials (hip and lower abdominal surgery) have been concluded. To date, the results appear encouraging. Management believe that safety (eg respiratory depression and nausea) is not an issue for the drug.The company is also conducting an additional trial in C section patients which is completing enrollment and should be included in the European submission for Depomorphine later this year. We expect the pivotal trial data for Depomorphine to be presented at the American Society of Clinical Anaesthesiologists in October 2003.

Paxil CR continues to grow (accounting for c.26% of total Paxil scrips in the US). 50% of these Paxil CR scrips are repeat and Paxil CR accounts for c.7% of the total SSRI antidepressant market in the US. Paxil CR is already filed for pre-menstrual dysphoria disorder (PMDD). However, GSK also plans to submit the intermittent treatment of PMDD later this year.

SKP also confirmed that Quintiles plans to present new data for Solaraze at the American Society of Dermatology in March. SKP believes that Solaraze is making in-roads into the actinic keratosis market and appears to be taking market share from Ephedrex (5-FU). Clinical trials in Australia are on track, with SKP planning to submit Solaraze to the Australian regulatory authorities in 2004 (second largest market opportunity after the US).

Enzon has already started to market DepoCyt in the US and SKP expects to see wider usage of the drug by key oncologists in the next few months. Phase IV studies for the neoplastic meningitis indication are on track, with an FDA Advisory Committee meeting (ODAC) scheduled next month.

Overall, we expect the newsflow for SKP to continue and reiterate our BUY recommendation with a price objective of 80p (based on applying the speciality pharma multiple to our 06E EPS of 14p and discounting back agressively at 30% p.a.). Risks to the stock include the general risk of drug development delay and product approval failure.

driver - 20 Apr 2012 15:24 - 187 of 202

Forgot I still had these up 114% today can't be bad.

Flutiform Positive Outcome

driver - 20 Apr 2012 17:03 - 188 of 202

Good finish 106% not bad.

driver - 22 Apr 2012 17:33 - 189 of 202

SkyePharma soars on asthma drug approval

ahoj - 25 Apr 2012 09:09 - 190 of 202

It was 50p about five years ago when they were talking about this. that's equal to £50 now, due to 100 to 1 split!

How much does it worth now?

driver - 25 Apr 2012 10:28 - 191 of 202


Not Much.

ahoj - 25 Apr 2012 10:36 - 192 of 202

But you are holding these. What do you mean?
Can it be subject of a bid given its portfolio..?

driver - 25 Apr 2012 15:22 - 193 of 202


Not much, as I am only holding a few I bottom drawed these after the consolidation and didn’t top up, if it ten bags from here I might be interested.

ahoj - 25 Apr 2012 15:27 - 194 of 202

I had 100k before consolidation, started adding again since the report. Finger crossed.

driver - 25 Apr 2012 15:34 - 195 of 202


Good luck, have a look at RGM,s news today Massive jorc.

ahoj - 27 Apr 2012 10:12 - 196 of 202

thanks driver. It can be fice bagger this year.

driver - 28 Apr 2012 10:39 - 197 of 202

Edison Update
27 April 2012

driver - 22 Jun 2012 10:54 - 198 of 202

SkyePharma Announces Successful Completion of
flutiform® Japanese Clinical Trial Programme

ahoj - 22 Jun 2012 11:22 - 199 of 202

It should be 5 rather than 0.75!! IMO

ahoj - 03 Jul 2012 12:34 - 200 of 202

European Commission Positive Decision on flutiform®
- flutiform® to be Approved in 21 Countries in Europe

I need five fold increase to recover my original money I invested 8 years ago.

goldfinger - 10 Oct 2014 11:16 - 201 of 202

Just added here, excelent results yesterday, good stock to use as an hedge against falling prices elsewhere.


goldfinger - 10 Oct 2014 11:32 - 202 of 202

Broker forecasts....

09 Oct Oriel Securities Buy 329.63 460.00 460.00 Reiterates
09 Oct N+1 Singer Corporate 329.63 - - Reiterates
Register now or login to post to this thread.